EP4487836A1 — Aqueous composition comprising avermectins

USPTO Abstract

An aqueous composition is provided which comprises at least one surface modifier selected from a group consisting of cellulose derivatives, in particular hydroxypropylmethyl cellulose, methylcellulose and hydroxypropylcellulose, polyvinylpyrrolidones and derivatives thereof, alginates, carrageenan, collagens, polyoxyethylene-polyoxypropylene copolymers, polyalkylene glycols, lecithins, phospholipids, pegylated phospholipids, gelatine, cholesterol, casein, tragacanth, pectins, gums, especially gum arabic, dextran, polyoxyethylen stearates, polyvinyl alcohol, polyethylene glycols, triethanolamine, tocopherol-polyethylene glycols and combinations thereof in an amount from 0.05% by weight to 15% by weight, based on the total weight of the composition, at least one active pharmaceutical ingredient selected from the group of avermectins in an amount from 2% by weight to 15% by weight, based on the total weight of the composition, having a mean particle size of 0.01 µm to 20 µm, and water in an amount from 70% by weight to 97.9% by weight, based on the total weight of the composition. Preferably, the at least one active pharmaceutical ingredient selected from the group of avermectins is ivermectin. Further, the aqueous composition is preferably for use in a pharmaceutical composition or medicament, wherein preferably for the use in the prevention or treatment of viral diseases, in particular for use in the prevention or treatment of a SARS-Covid-2 infection or of a HIV infection.